ArticleJournal of kidney cancer and VHL2026
Prognostic Significance of NOTCH1-ICD Expression in Renal Cell Carcinoma.
Article in Journal of kidney cancer and VHL, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The NOTCH1 signaling pathway regulates proliferation, differentiation, and apoptosis, with its intracellular domain (NOTCH1-ICD) reflecting pathway activation. While NOTCH1 dysregulation has been linked to renal cell carcinoma (RCC), its prognostic significance across RCC subtypes remains unclear. In this study, we analyzed NOTCH1-ICD immunohistochemical expression in 101 RCC patients: 69 clear cell RCC (ccRCC), 15 papillary RCC (pRCC), and 17 chromophobe RCC (chRCC), and correlated results with clinicopathological features and survival. In ccRCC, high NOTCH1-ICD expression (>15% positive nuclei) identified a small subgroup of tumors with aggressive features and a trend toward poorer overall survival; however, in multivariate analysis, tumor grade emerged as the only independent prognostic factor (HR = 3.36, 95% CI: 1.07-10.49, p = 0.037), while NOTCH1 showed nonsignificant association with poorer survival (HR = 1.30, 95% CI: 0.87-1.93, p = 0.203). In contrast, chRCC and pRCC exhibited minimal NOTCH1-ICD expression, with no observable impact on survival. NOTCH1-ICD was also detected in tumor endothelial cells, suggesting potential vascular mimicry. These findings indicate that NOTCH1-ICD may reflect tumor aggressiveness in ccRCC and could have implications for targeted therapy, but its independent prognostic value requires validation in larger cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.